Abstract
We assessed whether expression of excision repair cross-complementation group 1 (ERCC1) and/or thymidylate synthase (TS) can predict clinical outcome after preoperative chemoradiotherapy (CRT) in patients with localised oesophageal cancer. Paraffin-embedded pretreatment tumour specimens collected by endoscopic biopsy from patients treated with preoperative CRT (5-fluorouracil/cisplatin or capecitabine/cisplatin plus radiation) were analysed by immunohistochemical assay. Between March 1993 and June 2005, 129 patients were treated with preoperative CRT followed by surgery; of these, 108 biopsy specimens were available for analysis, and 40% and 35% were positive for ERCC1 and TS, respectively. Patients with ERCC1-negative (p < 0.001) or TS-negative (p = 0.04) tumours were significantly more likely to achieve pathologic major response. In multivariate analysis, ERCC1 was the only independent variable predicting pathologic response (p < 0.001). Patients with ERCC1-negative tumours showed tendencies toward prolonged overall survival (p = 0.10) and event free survival (p = 0.08). Prospective studies are required to determine the benefit of preoperative CRT in ERCC1-negative tumours.
Original language | English (US) |
---|---|
Pages (from-to) | 54-60 |
Number of pages | 7 |
Journal | European Journal of Cancer |
Volume | 44 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Externally published | Yes |
Keywords
- Combined modality therapy
- ERCC1
- Oesophageal neoplasms
ASJC Scopus subject areas
- Oncology
- Cancer Research